Burney Co. Cuts Stock Position in Cencora, Inc. $COR

Burney Co. decreased its position in shares of Cencora, Inc. (NYSE:COR) by 10.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,245 shares of the company’s stock after selling 10,703 shares during the period. Cencora comprises 0.9% of Burney Co.’s investment portfolio, making the stock its 18th biggest position. Burney Co.’s holdings in Cencora were worth $28,204,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC lifted its position in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC increased its stake in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after buying an additional 43 shares during the period. Caldwell Trust Co acquired a new stake in Cencora during the 2nd quarter worth approximately $46,000. Capital A Wealth Management LLC boosted its position in Cencora by 3,975.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after buying an additional 159 shares during the period. Finally, Twin Peaks Wealth Advisors LLC acquired a new position in shares of Cencora in the second quarter worth $52,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of NYSE COR opened at $341.12 on Friday. The stock’s 50-day simple moving average is $348.66 and its 200-day simple moving average is $314.86. The firm has a market capitalization of $66.17 billion, a PE ratio of 42.91, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the prior year, the company posted $3.34 earnings per share. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. UBS Group lifted their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. TD Cowen increased their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Barclays began coverage on Cencora in a research report on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective for the company. Mizuho raised their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $373.25.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 20,317 shares of company stock worth $7,009,260 over the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.